ANRS Prévenir: Renal Safety of Different TDF/FTC Dosing Regimens for HIV PrEP

Source: Clinical Impact of New HIV Data From EACS 2021*
Download Slideset
October 27-30, 2021; London, United Kingdom
Renal safety of daily TDF/FTC for PrEP acceptable, with few serious renal adverse events and none leading to permanent treatment discontinuation.
Format: Microsoft PowerPoint (.ppt)
File Size: 179 KB
Released: November 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Commentary from Dr Yan Zhao on the latest findings from EACS 2021 highlighting the unique challenges of older people living with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 30, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 30, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue